Veru Inc. (VERU)
| Previous close | 1.2100 |
| Open | 1.2400 |
| Bid | 1.2500 x 2800 |
| Ask | 1.2800 x 2800 |
| Day's range | 1.2100 - 1.2800 |
| 52-week range | 0.3600 - 1.9200 |
| Volume | |
| Avg. volume | 2,441,527 |
| Market cap | 185.904M |
| Beta (5Y monthly) | -0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7000 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 28 Apr 2014 |
| 1y target est | 2.75 |
GlobeNewswireVeru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two late-breaking abstract presentations at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting, taking place May 9-11, 2024 in New Orleans, LA. The
ZacksWhat Makes Veru (VERU) a New Buy Stock
Veru (VERU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire
Veru Announces Date of 2024 Annual Meeting of Shareholders
--2023 Form 10-K/A and Q1 2024 Form 10-Q filed today-- --2024 Annual Meeting of Shareholders will be June 18, 2024 -- MIAMI, FL, April 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company has now filed both an amendment to its Annual Report on Form 10-K/A f
